Syndax Pharmaceuticals Inc revenue
Syndax Pharmaceuticals Inc's revenue was $172m in fiscal 2025, up 627.8% on the year before. Since fiscal 2015 ($627,000) it has grown at a compound 75.4% a year. Over the last twelve months it was $290m.
Revenue history
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 2 | 2 | 2 | 2 | 140 | 0 | 0 | 24 | 172 | 290 |
| Growth on the year before | — | +94.6% | +72.8% | −28.0% | 0.0% | 0.0% | +>999% | −100.0% | — | — | +627.8% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Net Product Revenues | $125M | 72.4% | ▲ 1525.6% |
| Collaboration Revenue | $42.4M | 24.6% | — |
| Milestone Revenue | $5.1M | 3.0% | ▼ 67.9% |
From Syndax Pharmaceuticals Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Syndax Pharmaceuticals Inc | $290m | 159.7% | 177.8% |
| Protagonist Therapeutics, Inc | $282m | 34.8% | — |
| Vir Biotechnology, Inc. | $303m | 1495.9% | -14.8% |
| Phathom Pharmaceuticals, Inc. | $275m | 86.8% | — |
| Vericel Corp | $306m | 23.0% | 19.8% |
| Adaptive Biotechnologies Corp | $308m | 50.1% | 17.6% |
Compare with peers
- Protagonist Therapeutics, Inc revenue
- Vir Biotechnology, Inc. revenue
- Phathom Pharmaceuticals, Inc. revenue
- Vericel Corp revenue
- Adaptive Biotechnologies Corp revenue
Head to head: PTGX vs SNDXSNDX vs VIRPHAT vs SNDX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies